Taking Diabetes to Heart—Deregulation of Myocardial Lipid Metabolism in Diabetic Cardiomyopathy
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Heart disease is the leading cause of death in patients with diabetes.[1][1] Although advances in medical management and lifestyle interventions have reduced cardiovascular mortality in diabetic patients by as much as 40% over the last decade, the actual number of deaths is predicted to rise as a
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093 · cited 1×
“This relationship between FA and glucose metabolism, first described by Philip Randle in 1963, is known as the glucose–FA cycle or the Randle cycle.(63)”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
Forman, B. M., Chen, J., & Evans, R. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4312 · Cited by 2,116
Role of diabetes in congestive heart failure: The Framingham study
Kannel, W. B., Hjortland, M., & Castelli, W. P. (1974) · The American Journal of Cardiology · doi:10.1016/0002-9149(74)90089-7 · Cited by 2,090
Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.-W., Karin, M., & Shoelson, S. E. (2001) · Science · doi:10.1126/science.1061620 · Cited by 1,884
Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study
Garcia, M. J., McNamara, P. M., Gordon, T., & Kannell, W. B. (1974) · Diabetes · doi:10.2337/diab.23.2.105 · Cited by 1,608
Yu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. K., Cushman, S. W., Cooney, G. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200958200 · Cited by 1,561
Diabetic Cardiomyopathy Revisited
Boudina, S., & Abel, E. D. (2007) · Circulation · doi:10.1161/circulationaha.106.679597 · Cited by 1,543
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 6×
“Common Pathways for Cardiac Dysfunction in Diabetes Once metabolic preference is given to FAs and the heart moves away from glucose oxidation, the downstream changes are similar between T1DM and T2DM.”
BackgroundInfluentialItani, S. I., Ruderman, N. B., Schmieder, F., & Boden, G. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2005 · Cited by 1,390
Manninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329
Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311
Griffin, M. E., Marcucci, M. J., Cline, G. W., Bell, K., Barucci, N., Lee, D., Goodyear, L. J., Kraegen, E. W., White, M. F., & Shulman, G. I. (1999) · Diabetes · doi:10.2337/diabetes.48.6.1270 · Cited by 1,267
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Malmberg, K., Rydén, L., Wedel, H., Birkeland, K., Bootsma, A., Dickstein, K., Efendic, S., Fisher, M., Hamsten, A., Herlitz, J., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi199 · Cited by 1,048
Copps, K. D., & White, M. F. (2012) · Diabetologia · doi:10.1007/s00125-012-2644-8 · Cited by 1,017 · cited 2×
“However, phosphorylation of residues adjacent to the PI3K binding sites by serine kinases displaces PI3K and thus interferes with its ability to activate IRS1.(90,94) The inhibitory effect of free FAs on IRS1 and insulin signaling was demonstrated in cell culture,(95,96) animal models, and human volunteers(100) and ma…”
BackgroundMyocardial Cell Death in Human Diabetes
Frustaci, A., Kajstura, J., Chimenti, C., Jakoniuk, I., Leri, A., Maseri, A., Nadal-Ginard, B., & Anversa, P. (2000) · Circulation Research · doi:10.1161/01.res.87.12.1123 · Cited by 796 · cited 1×
“Ventricular biopsies from type 2 diabetic patients demonstrate increased apoptosis, consistent with the activation of lipotoxic mechanisms, although the cause-and-effect relationship with toxic lipid species has not been established.(164) To further elucidate the role of cardiac lipotoxicity in humans, noninvasive in…”
BackgroundIntramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart
Sharma, S., Adrogue, J. V., Golfman, L., Uray, I., Lemm, J., Youker, K., Noon, G. P., Frazier, O. H., & Taegtmeyer, H. (2004) · The FASEB Journal · doi:10.1096/fj.04-2263com · Cited by 790 · cited 1×
“In human patients with T2DM and heart failure, a dramatic accumulation of lipids within the myocardium and restructuring of the lipid metabolic gene expression profile were observed.(36) In addition, McGavoc et al found intramyocardial lipid deposits in diabetic patients with normal cardiac function, suggesting that m…”
BackgroundPeterson, L. R., Herrero, P., Schechtman, K. B., Racette, S. B., Waggoner, A. D., Kisrieva-Ware, Z., Dence, C., Klein, S., Marsala, J., Meyer, T., et al. (2004) · Circulation · doi:10.1161/01.cir.0000127959.28627.f8 · Cited by 656
Cardiac Steatosis in Diabetes Mellitus: A 1 H-Magnetic Resonance Spectroscopy Study
McGavock, J. M., Lingvay, I., Zib, I., Tillery, T., Salas, N., Unger, R., Levine, B. D., Raskin, P., Victor, R. G., & Szczepaniak, L. S. (2007) · Circulation · doi:10.1161/circulationaha.106.645614 · Cited by 612 · cited 1×
“In addition, McGavoc et al found intramyocardial lipid deposits in diabetic patients with normal cardiac function, suggesting that metabolic disturbances may precede the onset of left ventricular dysfunction.(37) Functionally, positron emission tomography studies of human patients with T1DM revealed increased myocardi…”
ResultNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575
Disorders of carnitine transport and the carnitine cycle
Longo, N., Amat di San Filippo, C., & Pasquali, M. (2006) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30087 · Cited by 543 · cited 1×
“inner mitochondrial membrane by a carnitine-acylcarnitine translocase that exchanges acylcarnitine for carnitine.(62)”
BackgroundRutter, M. K., Parise, H., Benjamin, E. J., Levy, D., Larson, M. G., Meigs, J. B., Nesto, R. W., Wilson, P. W. F., & Vasan, R. S. (2003) · Circulation · doi:10.1161/01.cir.0000045671.62860.98 · Cited by 511
Lipid accumulation in non-adipose tissue and lipotoxicity
van Herpen, N. A., & Schrauwen-Hinderling, V. B. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.049 · Cited by 500
PKC-θ knockout mice are protected from fat-induced insulin resistance
Kim, J. K., Fillmore, J. J., Sunshine, M. J., Albrecht, B., Higashimori, T., Kim, D.-W., Liu, Z.-X., Soos, T. J., Cline, G. W., O’Brien, W. R., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422230 · Cited by 500
Regulation of energy substrate metabolism in the diabetic heart
Stanley, W. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00047-3 · Cited by 480 · cited 1×
“increased FA oxidation, decreased glucose utilization, and decreased insulin sensitivity, and recent data indicate that these changes may be detrimental to cardiac function.(70) In addition to commonly used treatments in T2DM, such as PPAR agonists and metformin, myocardial substrate utilization can be modulated by in…”
BackgroundRegulation of pyruvate dehydrogenase complex activity by reversible phosphorylation
Holness, M. J., & Sugden, M. C. (2003) · Biochemical Society Transactions · doi:10.1042/bst0311143 · Cited by 479
Mazumder, P. K., O’Neill, B. T., Roberts, M. W., Buchanan, J., Yun, U. J., Cooksey, R. C., Boudina, S., & Abel, E. D. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2366 · Cited by 437
Tanti, J.-F., & Jager, J. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.07.004 · Cited by 430
Diamant, M., Lamb, H. J., Groeneveld, Y., Endert, E. L., Smit, J. W. A., Bax, J. J., Romijn, J. A., de Roos, A., & Radder, J. K. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00625-9 · Cited by 372
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309 · cited 1×
“However, the use of certain forms of glitazones, which are PPARc agonists, is associated with edema, plasma volume expansion, and the development of congestive heart failure, thus limiting their use.(68,69)”
BackgroundBouzakri, K., Roques, M., Gual, P., Espinosa, S., Guebre-Egziabher, F., Riou, J.-P., Laville, M., Le Marchand-Brustel, Y., Tanti, J.-F., & Vidal, H. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1319 · Cited by 305
Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts
McCormack, J. G., Barr, R. L., Wolff, A. A., & Lopaschuk, G. D. (1996) · Circulation · doi:10.1161/01.cir.93.1.135 · Cited by 291 · cited 1×
“Similar to trimetazidine, ranolazine have been shown to suppress FA oxidation in rat cardiac and skeletal muscle and result in a reciprocal increase in glucose oxidation.(233) Recent reports also implicate the ability of ranolazine to inhibit the late inward sodium channel, which”
ResultSolinas, G., Naugler, W., Galimi, F., Lee, M.-S., & Karin, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607626103 · Cited by 284
Increased Rates of Fatty Acid Uptake and Plasmalemmal Fatty Acid Transporters in Obese Zucker Rats
Luiken, J. J. F. P., Arumugam, Y., Dyck, D. J., Bell, R. C., Pelsers, M. M. L., Turcotte, L. P., Tandon, N. N., Glatz, J. F. C., & Bonen, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100052200 · Cited by 282
Malmberg, K., Ryden, L., Hamstent, A., Herlitz, J., Waldenstrom, A., Wedel, H., & on behalf of the DIGAMI study group (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015067 · Cited by 281 · cited 1×
“The Diabetic Patients with Acute MI study showed that intensive insulin and glucose infusion during acute myocardial infarction followed by subcutaneous insulin therapy for 3 months after myocardial infarction reduced mortality in diabetic patients.(179) However, the Polish GIK trial did not demonstrate any decrease i…”
BackgroundLuiken, J. J. F. P., Koonen, D. P. Y., Willems, J., Zorzano, A., Becker, C., Fischer, Y., Tandon, N. N., van der Vusse, G. J., Bonen, A., & Glatz, J. F. C. (2002) · Diabetes · doi:10.2337/diabetes.51.10.3113 · Cited by 260
Noyan-Ashraf, M. H., Shikatani, E. A., Schuiki, I., Mukovozov, I., Wu, J., Li, R.-K., Volchuk, A., Robinson, L. A., Billia, F., Drucker, D. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.091215 · Cited by 259 · cited 1×
“Recent reports have also demonstrated that GLP-1 therapeutics have beneficial effects on the cardiovascular system; for example, the GLP-1 analogue liraglutide improves cardiac function in db/db mice and streptozotocininduced diabetic rats via downregulation of endoplasmic reticulum stress.(201,202) In addition, GLP-1…”
BackgroundCD36 Deficiency Rescues Lipotoxic Cardiomyopathy
Yang, J., Sambandam, N., Han, X., Gross, R. W., Courtois, M., Kovacs, A., Febbraio, M., Finck, B. N., & Kelly, D. P. (2007) · Circulation Research · doi:10.1161/01.res.0000264104.25265.b6 · Cited by 246
PPAR-α–Null Mice Are Protected From High-Fat Diet–Induced Insulin Resistance
Guerre-Millo, M., Rouault, C., Poulain, P., André, J., Poitout, V., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Reach, G., & Staels, B. (2001) · Diabetes · doi:10.2337/diabetes.50.12.2809 · Cited by 241
Impaired cardiac contractile function in ventricular myocytes from leptin-deficient ob/ob obese mice
Dong, F., Zhang, X., Yang, X., Esberg, L. B., Yang, H., Zhang, Z., Culver, B., & Ren, J. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06241 · Cited by 155
Lebeche, D., Davidoff, A. J., & Hajjar, R. J. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1347 · Cited by 122
Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes
Severson, D. L. (2004) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y04-065 · Cited by 111
Cited by
Metabolic remodelling in heart failure
Bertero, E., & Maack, C. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0044-6 · Cited by 706
Chronic Heart Failure and Inflammation: What Do We Really Know?
Dick, S. A., & Epelman, S. (2016) · Circulation Research · doi:10.1161/circresaha.116.308030 · Cited by 692
Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes
Shah, M. S., & Brownlee, M. (2016) · Circulation Research · doi:10.1161/circresaha.116.306923 · Cited by 602
Molecular mechanism of doxorubicin-induced cardiomyopathy – An update
Renu, K., V.G., A., P.B., T. P., & Arunachalam, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.043 · Cited by 588
Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes
Seferović, P. M., & Paulus, W. J. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv134 · Cited by 552
Metadata
- Authors
- Bayeva, M., Sawicki, K. T., & Ardehali, H.
- Venue
- Journal of the American Heart Association
- Published
- 2013-11-18
- Volume
- 2
- Issue
- 6
- Pages
- e000433-e000433
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2137689126
- Cited by
- 156
- References
- 45
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.